新型冠状病毒

US FDA panel backs Novavax Covid jab with hopes of persuading sceptics

Protein-based vaccine is an alternative to mRNA technology used by BioNTech/Pfizer and Moderna

US government advisers have recommended the approval of a fourth Covid-19 jab developed by Novavax, expressing hopes that it can help boost the nation’s flagging immunisation programme as a new wave of infections sweeps across the population.

Scientists on a US Food and Drug Administration advisory panel on Tuesday voted overwhelmingly in favour of authorising the first protein-based Covid vaccine — a type of technology that has been used for decades against diseases including shingles and the flu.

Some healthcare experts believe the vaccine could win over vaccine sceptics who have so far resisted getting jabs. Anti-vaccine campaigners have taken aim at shots developed by BioNTech/Pfizer and Moderna, despite their effectiveness, over their use of mRNA, a new technology.

您已阅读22%(781字),剩余78%(2788字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。
设置字号×
最小
较小
默认
较大
最大
分享×